NCT03496870View on ClinicalTrials.gov

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 8, 2018

Primary Completion Date

July 2, 2018

Study Completion Date

July 2, 2018

Conditions
Parkinson Disease
Interventions
DRUG

Opicapone

catechol-O-methyltransferase (COMT) inhibitor

DRUG

Carbidopa Levodopa

Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor

Trial Locations (3)

48334

Neurocrine Clinical Site, Farmington Hills

90806

Neurocrine Clinical Site, Long Beach

91206

Neurocrine Clinical Site, Glendale

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY